2. Epigenetics TGF-beta/Smad Neuronal Signaling Metabolic Enzyme/Protease Apoptosis
  3. PKC CaMK Phosphatase Apoptosis
  4. DCP-LA

DCP-LA (FR236924), a linoleic acid derivative, selectively and directly activates PKCε. DCP-LA activates Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) and inhibits protein phosphatase-1 (PP-1) to stimulate AMPA receptor exocytosis. DCP-LA inhibits activation of caspase-3/-9 and protects neurons at least in part from oxidative stress-induced apoptosis.

For research use only. We do not sell to patients.

DCP-LA Chemical Structure

DCP-LA Chemical Structure

CAS No. : 28399-31-7

Size Price Stock Quantity
Liquid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 112 In-stock
Solution
10 mM * 1 mL in DMSO USD 112 In-stock
Liquid
1 mg USD 99 In-stock
5 mg USD 165 In-stock
10 mg USD 231 In-stock
25 mg USD 462 In-stock
50 mg USD 792 In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 4 publication(s) in Google Scholar

Other Forms of DCP-LA:

DCP-LA Related Antibodies

Top Publications Citing Use of Products

View All PKC Isoform Specific Products:

View All Isoforms
PKC PKCα PKCβ PKCγ PKCδ PKCε PKCη PKCζ PKCθ PKCμ PKC-ι ℩ PKCι

View All CaMK Isoform Specific Products:

View All Isoforms
CaMK III CaMK II

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

DCP-LA (FR236924), a linoleic acid derivative, selectively and directly activates PKCε. DCP-LA activates Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) and inhibits protein phosphatase-1 (PP-1) to stimulate AMPA receptor exocytosis. DCP-LA inhibits activation of caspase-3/-9 and protects neurons at least in part from oxidative stress-induced apoptosis[1][2][3].

IC50 & Target[1][3]

PKCε

 

CaMK II

 

In Vitro

DCP-LA (100 nM; 15 min) activates cytosolic PKCε by binding to the phosphatidylserine binding/associating sites Arg50 and Ile89, without translocation towards the cell surface in PL-12 cells[1].
DCP-LA (10, 100, 100 nM; 10 min; 35 ℃) activates CaMKII and inhibits PP-1 in rat hippocampal neurons[2].
DCP-LA (100 nM; 20 min) increases expression of the receptors on the plasma membrane, responsible for potentiate AMPA receptor responses in rat hippocampal slices[2].
DCP-LA (100 nM; 10 min) results facilitation of hippocampal synaptic transmission[2].
DCP-LA (100 nM; 24 h) prevents the Sodium nitroprusside (SNP, HY-10219) effect and rescues neurons from SNP-induced degradation[3].
DCP-LA (100 nM; 12 h) abolishes the caspase-3/9 activation induced by (SNP, HY-10219) (1 mM)[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

DCP-LA Related Antibodies

Cell Viability Assay[3]

Cell Line: Rat cerebral cortical neurons
Concentration: 100 nM
Incubation Time: 24 hours; accompanied with 1 mM Sodium nitroprusside (SNP)
Result: Prevented SNP-induced neuronal cell death.
In Vivo

DCP-LA (1 mg/kg; p.o.; once daily; 7 d) exhibits a protective effect against ischemic brain damage, decreasing cerebral cortical defect due to middle cerebral artery (MCA) occlusion in mouse model[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Middle cerebral artery (MCA) occlusion in mouse model (male CB-17 mice, 5-8 weeks old)[3]
Dosage: 1 mg/kg
Administration: Oral gavage; once daily for 7 days; sacrificed mice on days 28
Result: Significantly diminished degraded area due to cerebral infarction, with the rescued area reaching 82%.
Molecular Weight

308.50

Formula

C20H36O2
CAS No.
Appearance

Liquid (Density: 0.968 g/cm3)

Color

Colorless to light yellow

SMILES

O=C(O)CCCCCCCC1C(CC2C(CCCCC)C2)C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 5 mg/mL (16.21 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.2415 mL 16.2075 mL 32.4149 mL
5 mM 0.6483 mL 3.2415 mL 6.4830 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 0.5 mg/mL (1.62 mM); Clear solution

    This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 0.5 mg/mL (1.62 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 0.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: ≥98.0%

SDS (393 KB)

COA (239 KB) HNMR (299 KB) LCMS (417 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.2415 mL 16.2075 mL 32.4149 mL 81.0373 mL
5 mM 0.6483 mL 3.2415 mL 6.4830 mL 16.2075 mL
10 mM 0.3241 mL 1.6207 mL 3.2415 mL 8.1037 mL
15 mM 0.2161 mL 1.0805 mL 2.1610 mL 5.4025 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

DCP-LA Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

DCP-LA28399-31-7FR236924FR 236924FR-236924PKCCaMKPhosphataseApoptosisProtein kinase CCalmodulin-dependent protein kinasesCalmodulin-dependent kinaseslinoleic acid derivativeAMPA receptor exocytosisneuronsoxidative stress-inducedtranslocationInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
DCP-LA
Cat. No.:
HY-108599
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.